A 24 Weeks, Multicenter, Randomized, Double-blind, Placebo, Parallel-controlled Phase IIb Trail Comparing the Efficacy and Safety of MDR-001 Tablet Versus Placebo in Subjects With Overweight or Obesity
Latest Information Update: 27 Sep 2024
At a glance
- Drugs MDR-001 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors MindRank
- 27 Sep 2024 New trial record